US Pharma MarketingThe post Osel and partners launch Phase IIb FLIP-2 trial of Lactin-V appeared first on Clinical Trials Arena.
Osel and partners launch Phase IIb FLIP-2 trial of Lactin-V
Osel, together with Imperial College London’s Clinical Trials Unit and March of Dimes, has launched the Phase IIb FLIP-2 trial, assessing the efficacy and safety of Lactin-V, a microbiome-based therapy, in pregnant women at high risk of PTB. The trial builds on findings from the FLIP-1 Phase I study, which was conducted at the March of Dimes PRC. FLIP-1 results showed Lactin-V was safe, well-tolerated, and reduced preterm birth rates compared to historical controls. Credit: Peakstock / Shutterstock.com. Osel, Imperial College London’s clinical trials unit and March of Dimes have launched the Phase IIb FLIP-2 trial, assessing the efficacy and…
Osel, together with Imperial College London’s Clinical Trials Unit and March of Dimes, has launched the Phase IIb FLIP-2 trial, assessing the efficacy and safety of Lactin-V, a microbiome-based therapy, in pregnant women at high risk of PTB.
Source: Clinical Trials Arena